Infusible disease-modifying treatment — that is, therapies given intravenously — might have greater benefits for younger people with multiple sclerosis (MS) than oral ones, new research suggests.
The research was presented at the ongoing American Academy of Neurology (AAN)’s annual meeting (May 4-10) by Brandi Vollmer, MPH, a research assistant in neurology at the University of Colorado. The presentation was titled “Higher Efficacy Therapies Appear to have a Disproportionately Larger Effect in Younger Patients with Multiple Sclerosis.”
Previous research by the same group suggested that infusible, or IV, therapies — specifically rituximab (a therapy prescribed off-label to MS patients) and Tysabri (natalizumab; an approved MS therapy marketed by Biogen) — were more effective at preventing disease progression than oral MS therapies, namely Gilenya (fingolimod, marketed by Novartis) and Tecfidera (dimethyl fumarate, marketed by Biogen).
However, it is hard to predict how any specific patient will respond to a given therapy — for instance, some people with MS do very well on oral therapies. Thus, the researchers wanted to gain a clearer idea about which patients would most likely benefit from a certain type of treatment.
Researchers analyzed data from 1,004 patients with relapsing-remitting MS (RRMS) who were treated with one of these four therapies at the Rocky Mountain MS Center at the University of Colorado.
About half of the patients (509) took oral therapies (Gilenya and Tecfidera), while the rest (495 patients) were prescribed infusible therapies (Tysabri and rituximab). Patients were followed for up to two years, or until they stopped treatment.
The team specifically assessed disease activity over time — defined as either a clinical relapse or the appearance of new lesions in the brain, assessed through magnetic resonance imaging (MRI).
As in their previous research, the team found that, overall, a lower proportion of people given IV therapy experienced disease activity (21.2%) as compared with those taking oral medications (36.3%).
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?